论文部分内容阅读
目的观察培美曲塞+顺铂联合艾迪注射液对非小细胞肺癌患者的疗效。方法观察组32例(肺鳞癌13例、肺腺癌19例,Ⅱ期7例,Ⅲa期8例,Ⅲb期11例,Ⅳ期6例),对照组32例(肺鳞癌12例、肺腺癌20例,Ⅱ期7例,Ⅲa期8例,Ⅲb期10例,Ⅳ期7例)治疗结束对两组患者的有效率、疾病控制率、白细胞下降及Karnof-sky评分进行评价。结果观察组总有效率为62.5%,疾病控制率为84.3%;对照组总有效率为34.4%,疾病控制率为59.4%;治疗前后的白细胞总数下降在Ⅲ°以上发生率,观察组为12.5%;对照组为28.3%;Karnof sky评分:观察组改善者18例,稳定者8例,对照组改善者12例,稳定者7例;两组间差异有统计学意义(P<0.05)。结论培美曲塞+顺铂方案联合艾迪注射液对非小细胞肺癌患者有较良好的疗效。
Objective To observe the efficacy of pemetrexed + cisplatin combined with Aidi injection in patients with non-small cell lung cancer. Methods The observation group consisted of 32 cases (13 cases of lung squamous cell carcinoma, 19 cases of lung adenocarcinoma, 7 cases of stage Ⅱ, 8 cases of stage Ⅲa, 11 cases of stage Ⅲb and 6 cases of stage Ⅳ) and 32 cases of lung squamous carcinoma 20 cases of lung adenocarcinoma, 7 cases of stage Ⅱ, 8 cases of stage Ⅲa, 10 cases of stage Ⅲb and 7 cases of stage Ⅳ. The efficacy, disease control rate, leukopenia and Karnof-sky score of the two groups were evaluated at the end of treatment. Results The total effective rate in the observation group was 62.5% and the disease control rate was 84.3%. The total effective rate in the control group was 34.4% and the disease control rate was 59.4%. The total leukocyte count before and after treatment was above Ⅲ ° and the observation group was 12.5 %; Control group was 28.3%; Karnof sky score: the observation group improved 18 cases, stable in 8 cases, control group improved in 12 cases, stable in 7 cases; the difference between the two groups was statistically significant (P <0.05). Conclusion Pemetrexed combined with cisplatin combined with Aidi injection for patients with non-small cell lung cancer have a good effect.